In vitro antiviral activity of cabotegravir against HIV-2.

We examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naïve individuals. HIV-2 was sensitive to cabotegravir in both single-cycle and spreading infection assays, with EC50 values in the low to sub-nanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for ART and PrEP in HIV-2-prevalent settings.
PMID: 30012774 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - July 16, 2018 Category: Microbiology Authors: Smith RA, Wu VH, Zavala CG, Raugi DN, Ba S, Seydi M, Gottlieb GS, University of Washington-Dakar HIV-2 Study Group Tags: Antimicrob Agents Chemother Source Type: research